Clinical Trials
Clinical trials are the driving force behind our efforts to advance innovative therapies that may help patients and their families fighting a broad range of cancers. We conduct these trials to support the development of medicines that have the potential to be safe and effective options for our patients.
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
NCT05538572
Description of the Study
This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors. The purpose of this study is to investigate the safety, tolerability, dose limiting toxicity, and to determine maximally tolerated dose and recommended phase 2 dose to be used in subsequent development of PRT3645.
Eligibility:
Age18+
Sex All
StatusRecruiting